Upgrade to SI Premium - Free Trial

Regulus Therapeutics (RGLS) Selloff 'Overdone' - Wedbush

March 12, 2018 11:08 AM
Wedbush analyst Liana Moussatos said the sell-off in Regulus Therapeutics (NASDAQ: RGLS) is overdone. The firm reiterated an ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments Analyst PT Change

Next Articles